Q1 Earnings Estimate for IPSC Issued By HC Wainwright

Century Therapeutics, Inc. (NASDAQ:IPSC) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Century Therapeutics in a research note issued on Tuesday, May 27th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings per share of ($0.40) for the quarter. HC Wainwright has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Century Therapeutics’ Q2 2026 earnings at ($0.41) EPS, Q3 2026 earnings at ($0.39) EPS and FY2026 earnings at ($1.56) EPS.

Century Therapeutics (NASDAQ:IPSC) last posted its earnings results on Thursday, May 15th. The company reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $1.20. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. The firm had revenue of $109.16 million during the quarter, compared to analyst estimates of $45.52 million.

Other analysts also recently issued reports about the company. Guggenheim reiterated a “buy” rating on shares of Century Therapeutics in a research report on Friday, March 28th. Chardan Capital reduced their price target on shares of Century Therapeutics from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Friday, May 16th. Finally, Piper Sandler decreased their price objective on shares of Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating for the company in a report on Thursday, March 20th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Century Therapeutics presently has a consensus rating of “Buy” and an average price target of $4.20.

Century Therapeutics Stock Down 0.5%

NASDAQ IPSC opened at $0.56 on Wednesday. Century Therapeutics has a 52 week low of $0.34 and a 52 week high of $3.46. The company has a fifty day moving average of $0.51 and a two-hundred day moving average of $0.81. The firm has a market capitalization of $47.99 million, a price-to-earnings ratio of -0.30 and a beta of 1.80.

Institutional Trading of Century Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Marshall Wace LLP purchased a new stake in shares of Century Therapeutics during the 4th quarter valued at $36,000. Jane Street Group LLC lifted its holdings in shares of Century Therapeutics by 166.2% during the 4th quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock valued at $49,000 after purchasing an additional 29,992 shares during the last quarter. Two Sigma Advisers LP purchased a new stake in shares of Century Therapeutics during the 4th quarter valued at $52,000. Sei Investments Co. purchased a new stake in shares of Century Therapeutics during the 4th quarter valued at $53,000. Finally, AQR Capital Management LLC lifted its holdings in shares of Century Therapeutics by 358.9% during the 1st quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock valued at $53,000 after purchasing an additional 86,875 shares during the last quarter. Hedge funds and other institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.